Henry T. Greely
$27.95
Well before Jennifer Doudna and Emmanuelle Charpentier won the 2020 Chemistry Nobel for their discovery of genome editing tool CRISPR-Cas 9, Chinese scientist He Jiankui, in 2018, had attempted to render humans less susceptible to HIV, using the technique on non-identical twin girls. Greely, Deane F. and Kate Edelman Johnson, Professor of Law at Stanford Law School, writes extensively on bioethical issues asserts that He not only knew he had failed, he knew it before he implanted the edited embryos. Greely describes the procedure, the plusses and minuses of human gene-editing, concluding almost anything it does can be performed through existing, less risky methods. Greely deftly explores the religious and political concerns of gene-editing, and the need for regulation or banning of the technique altogether.
Orthogonal Adds Leading Academics on SPACs and Corporate Governance From Harvard and Stanford as Advisors
Professors Michael Klausner of Stanford and Guhan Subramanian of Harvard join advisory board of the Orthogonal SPAC Advantage Fund.
News provided by
Share this article
Share this article
NEW YORK, May 11, 2021 /PRNewswire/ Orthogonal, an asset management firm focused on legal and rule-driven investment opportunities, announced today the additions of Professor Michael Klausner of Stanford and Professor Guhan Subramanian of Harvard to the advisory board for its SPAC Advantage Fund.
Professor Klausner is the Nancy and Charles Munger Professor of Business and Professor of Law at Stanford Law School. He teaches and writes in the areas of corporate law, corporate governance, business transactions and financial regulation. Professor Klausner is a leading authority on SPACs and is frequently featured in the press. He is the author of
Human/monkey chimeric embryos: context and questions
Appeared in BioNews 1094 What is the moral status of these novel creatures? Scientists raise ethical concerns after lab creates a human-monkey HYBRID for cancer research – Headline from the Daily Mail
On 15 April 2021, the journal Cell published a paper reporting the creation of part monkey, part human embryos (see BioNews 1091). The international team of researchers had injected human stem cells into blastocysts (embryos about six days after fertilisation) of cynomolgus monkeys (aka crab-eating macaques ). Each blastocyst received 25 human cells, produced from a human donor s skin cells. Monkey blastocysts, like human blastocysts, normally must be transferred into a uterus by the sixth or seventh day to survive. These instead were treated with new methods allowing them to live in the lab for about 20 days. By the fourth day after the injection (tenth after fertilisation), about 100 embryos were still developing; that pl